A study to determine clinical outcomes in patients with advanced malignancies received treatment program (ICTriplex) and combination of ICTriplex to targeted therapy (TT)
Latest Information Update: 12 Jul 2022
At a glance
- Drugs Atezolizumab (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary) ; Bevacizumab; Erlotinib; Gemcitabine; Taxanes
- Indications Advanced breast cancer; Cervical cancer; Cholangiocarcinoma; Colorectal cancer; Gallbladder cancer; Gastric cancer; Glioblastoma; Hodgkin's disease; Lung cancer; Malignant melanoma; Ovarian cancer; Pancreatic cancer; Sarcoma; Solid tumours; Thymoma
- Focus Therapeutic Use
Most Recent Events
- 12 Jul 2022 New trial record
- 07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology